James V. Tricoli

National Institutes of Health — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

33h-index3.8kcitations150works1.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(47), Lung Cancer Treatments and Mutations(29), Sarcoma Diagnosis and Treatment(28), Genetic factors in colorectal cancer(11), Cancer-related Molecular Pathways(8)

Publications149 total

Supplementary Figure 3 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Figure 1 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Table 1 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Figure 2 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Data from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Table 3 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Data 1 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Table 2 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
supplementary table TS1 from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
2025Open Access
Supplementary Figure 3 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
2025Open Access
Supplementary Table 5 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
2025Open Access
Data from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
2025Open Access
Supplementary Table 1 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
2025Open Access
Supplementary Figure 6 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
2025Open Access
Supplementary Figure 8 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
2025Open Access
Supplementary Figure 7 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
2025Open Access
Supplementary Figure 9 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
2025Open Access
Supplementary Figure 5 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
2025Open Access
Supplementary Table 2 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
2025Open Access
Supplementary Table 6 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
2025Open Access
page 1 of 8Next →

Frequent Co-authors

P. Mickey Williams(15), Barbara A. Conley(11), Nita L. Seibel(11), David R. Patton(10), Lisa M. McShane(9), Brent Coffey(8), Naoko Takebe(8), Katherine A. Janeway(8), Lyndsay N. Harris(7), Douglas S. Hawkins(7), D. Williams Parsons(7), James H. Doroshow(6), Stanley R. Hamilton(6), Jin Piao(6), Lauren Saguilig(6), Todd A. Alonzo(6), Stacey L. Berg(6), Elizabeth Fox(6), Margaret Mooney(6), Thomas B. Shows(5)